AngioDynamics, Inc.
AngioDynamics, Inc. (Nasdaq: ANGO) is a medical technology company that designs, manufactures and sells devices used by clinicians to treat cardiovascular disease and cancer. Its products include systems for atherectomy, thrombectomy and tissue ablation, vascular access ports, angiographic and drainage catheters,… From the company’s description.
Over the twelve months to Aug 31, 2026, AngioDynamics, Inc. reported revenue of $325.38M, up 8.2% from a year earlier, and a net loss of $32.94M. Its operating margin was −11.2%, and operations generated $3.67M in cash. In fiscal 2025, it reported revenue of $320.17M, up 9.5% from fiscal 2024, and a net loss of $36.74M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What AngioDynamics, Inc. does
In the company’s own words
AngioDynamics, Inc. (Nasdaq: ANGO) is a medical technology company that designs, manufactures and sells devices used by clinicians to treat cardiovascular disease and cancer. Its products include systems for atherectomy, thrombectomy and tissue ablation, vascular access ports, angiographic and drainage catheters, guidewires, micropuncture kits and laser systems for treating varicose veins. Customers include hospitals and clinicians such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists and oncologists; sales are primarily through a direct U.S. sales force and through direct sales and distributors internationally. The company reports two segments: Med Tech, which includes products such as Auryon, AlphaVac, AngioVac and NanoKnife, and Med Device, which includes peripheral intervention, ports, venous insufficiency and ablation products. Its portfolio includes the SmartPort, BioFlo, VenaCure EVLT and Solero brands. AngioDynamics was founded in 1988 and has expanded through acquisitions, while divesting its dialysis, BioSentry, PICC and Midline businesses. It had approximately 632 full-time employees as of May 31, 2026. Its website is www.angiodynamics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- LATHAM, NY
- Fiscal year end
- May
- CIK
- 1275187
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns AngioDynamics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · AngioDynamics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do AngioDynamics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of AngioDynamics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in AngioDynamics, Inc.'s last four quarterly filings that the numbers alone won't show?”